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Background:  Myostatin (MSTN) is a negative regulator of muscle growth that may improve insulin sensitivity. We hypothesized that 
systemic MSTN inhibition would improve cardiomyocyte glucose metabolism in experimental heart failure (HF).
methods:  C57BL/6J mice were subjected to left anterior descending coronary artery ligation (HF) (n=19) or no ligation (SHAM) (n=9). 
Three weeks after surgery, HF was confirmed by echocardiography (echo) and HF animals received either drug (weekly 12mg/kg dose 
Myo-I, n=9) or vehicle (n=10), for 8 weeks. Myo-I is a MSTN neutralizing antibody that inhibits MSTN signaling. After treatment, echo was 
repeated, and mice were sacrificed.
results:  Myo-I treated HF mice displayed a significant improvement in cardiac function as seen by echo. Circulating serum MSTN and 
cardiac MSTN were significantly increased in HF; increased MSTN signaling, reflected by P-SMAD2,3, was confirmed in HF mice and was 
significantly reduced with Myo-I treatment. Abnormal glucose regulation was evident after HF, as shown by significantly reduced cardiac 
P-AMPK/AMPK, GLUT4 and P-AKT/AKT. In contrast, Myo-I normalized cardiac P-AMPK/AMPK, GLUT4 and P-AKT/AKT in HF mice.
Conclusion:  Abnormal cardiac glucose metabolism with dysregulation of MSTN is present in HF, and MSTN inhibition may improve 
cardiac glucose handling by altering AMPK and GLUT4. Further research to study how MSTN inhibition affects cardiac metabolism is 
warranted and may have important implications for HF therapy.
Table 1. Serum and cardiac protein changes in HF Mice.
SHAM
(n=9)
HF
(n=10) HF + Myo-I (n=9)
Fractional Shortening (% change after treatment) - -13.1 ± 4.9 41.8± 14.2#
Body weight (g) 29.3 2 ± 0.9 27.5 ± 1.3 31.4 ± 1.0#
Serum MSTN (pg/ml) 33,939 ± 2949 58,269 ± 2936* 47,959 ± 15142*#
Cardiac MSTN 100 ± 2 157 ± 2* 139 ± 5*#
Cardiac P-SMAD2/3
/SMAD 2/3 100 ± 3 155 ± 18* 96 ±12#
Cardiac P-AMPK /AMPK 100 ± 2 71 ± 7* 93 ± 1#
Cardiac GLUT4 100 ± 1 80 ± 1* 101 ± 2#
Cardiac P-AKT/AKT 100 ± 8 41 ± 5* 79 ± 9#
HF = Heart failure, *p<0.05 vs. SHAM, #p<0.05 vs. HF + Myo-I
